Cancer Lab · DeCure for X
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Bladder Adenocarcinoma — screening already-approved drugs against its 29-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for bladder adenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
isocitrate dehydrogenase (NADP(+)) 2 (IDH2) — IDH2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 5I96 · 1.55 Å · ligand NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NDP). Experimental structure, not a prediction.
A 10-year review of 28 patients with primary adenocarcinoma of the bladder, published in 1984, describes the lesion as highly aggressive but states that aggressive therapy is justified when feasible. A 2013 case report notes that bladder adenocarcinoma accounts for 0.5–2% of all malignant bladder tumours and that non-urothelial bladder tumours with intramural growth may delay symptom onset and diagnosis, adversely affecting prognosis compared with urothelial tumours. That report also states that bladder adenocarcinomas were traditionally believed to be resistant to both chemotherapy and radiotherapy, though it mentions recent advancements have shown encouraging responses with adjuvant chemotherapy and radiotherapy.
A population-based analysis, published in 1960 under a title about occupational competence and n-achievement of high school students, actually contains data on primary bladder adenocarcinoma. It reports that the prevailing treatment remains surgical intervention, while a sizable minority receives chemotherapy and/or radiation, often in combination with surgery.
No abstract provides response rates, survival figures, or sample sizes beyond the 28 patients in the 1984 series. The 2013 case report describes a single patient with primary urachal mucinous adenocarcinoma. No drug is named in any abstract, and no evidence of efficacy for any specific agent is given. The 1960 analysis does not report outcomes of the treatments it characterises.
What is missing is any prospective trial of chemotherapy or radiotherapy in bladder adenocarcinoma, any biomarker or molecular stratification that might identify responsive patients, and any funding for such trials given the rarity of the disease.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractAdenocarcinoma is an uncommon form of bladder carcinoma. We review our 10-year experience with primary adenocarcinoma of the bladder in 28 patients who were managed by a wide range of therapeutic modalities. Our data reaffirm the highly aggressive nature of this lesion. However, aggressive therapy is justified when feasible.
https://doi.org/10.1016/s0022-5347(17)50340-7AbstractUrinary bladder cancer is the second most frequent tumour of the genitourinary tract with bladder adenocarcinoma comprising for about 0.5-2% of all malignant bladder tumours. Other primary sites for such tumours include rectum, stomach, endometrium, breast, prostate, seminal vesicles and ovaries. Such non-urothelial bladder tumours with intramural bladder tumour growth may delay the onset of symptoms which may lead to a delay in the diagnosis and thereby adversely affecting the prognosis as compared to urothelial bladder tumours. Traditionally bladder adenocarcinomas were believed to be resistant to both chemotherapy and radiotherapy, but recent advancements have shown encouraging responses with adjuvant chemotherapy and radiotherapy. We present here a case of primary urachal mucinous adenocarcinoma of the urinary bladder highlighting their relative rarity of occurrence and the difficulties encountered in diagnosing primary bladder mucinous adenocarcinoma.
https://doi.org/10.7860/jcdr/2013/5597.2973AbstractThis study utilized a population-based analysis to showcase the utility of various prognostic features in primary bladder adenocarcinoma cases. In characterizing treatments, we find the prevailing treatment remains surgical intervention, whereas a sizable minority receives chemotherapy and/or radiation, often in combination with surgery.
https://doi.org/10.1016/j.clgc.2019.06.010Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
